Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Alberta

$25,000.00

Predictive hemoglobin response model development for effective anemia management

FY 2015-16

Summary
Renal disease patients with anemia are generally treated by the administration of recombinant human erythropoietin (rHuEPO) to adjust the hemoglobin (Hb) level. It has been recognized by the clinical community that an unstable Hb levels can lead to increased risk of mortality for the patients suffering from anemia. Conventional methods for guiding rHuEPO dosing are generally based on clinician's experiences and imprecise. Cybernius Medical Ltd. aims to develop an automatic decision support system to achieve effective anemia management. In this project, the objective is to develop a predictive model that would predict a patient's hemoglobin level response to rHuEPO dosing with an acceptable level of accuracy. The model will be used in future to develop an automatic decision making support system for anemia management using model based control technique. First-principle and data-driven methods will both be investigated to develop a model that is able to provide accurate Hb level predictions based on rHuEPO dosing. The large amount of renal disease patients suffering from anemia will benefit from the research with reduced risk of high Hb level variability. The research can also lead to reduced use of rHuEPO and the economic burden of patient, and reduce the clinician's time spent on anemia management.
Program
Engage Grants Program
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
479777-2015
Name nom
Li, Zukui
Department département
Chemical and Materials Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
1
Nb partie
1
Application title
Predictive hemoglobin response model development for effective anemia management
Keyword
NSERC
Application summary
Renal disease patients with anemia are generally treated by the administration of recombinant human erythropoietin (rHuEPO) to adjust the hemoglobin (Hb) level. It has been recognized by the clinical community that an unstable Hb levels can lead to increased risk of mortality for the patients suffering from anemia. Conventional methods for guiding rHuEPO dosing are generally based on clinician's experiences and imprecise. Cybernius Medical Ltd. aims to develop an automatic decision support system to achieve effective anemia management. In this project, the objective is to develop a predictive model that would predict a patient's hemoglobin level response to rHuEPO dosing with an acceptable level of accuracy. The model will be used in future to develop an automatic decision making support system for anemia management using model based control technique. First-principle and data-driven methods will both be investigated to develop a model that is able to provide accurate Hb level predictions based on rHuEPO dosing. The large amount of renal disease patients suffering from anemia will benefit from the research with reduced risk of high Hb level variability. The research can also lead to reduced use of rHuEPO and the economic burden of patient, and reduce the clinician's time spent on anemia management.